Abstract: Antibodies and compositions against Insulin-Like Growth Factor-1 Receptor (IGF-1R) and uses thereof are provided herein and antibodies and pharmaceutical compositions that can be used in methods of treating or reducing the severity of thyroid eye disease (TED) in subjects in need thereof, including reducing proptosis and Clinical Activity Score (CAS) in said subjects, by inhibiting the activity of IGF-1R with such antibodies and compositions.
Type:
Grant
Filed:
August 29, 2022
Date of Patent:
January 10, 2023
Assignee:
VIRIDIAN THERAPEUTICS, INC.
Inventors:
Vahe Bedian, Peter Harwin, Tomas Kiselak, Angela She, Jonathan Violin, Yang Zhao
Abstract: The present application addresses the problem of providing an Fc-binding protein having an improved antibody separation ability. The present application also addresses the problem of providing a high-accuracy antibody separation method using an insoluble carrier having the protein immobilized thereon. The problems can be solved by: an Fc-binding protein in which at least an amino acid substitution at a specific position therein occurs and which has reduced affinity for an antibody; and an antibody separation method including allowing an equilibration buffer solution to pass through a column in which an insoluble carrier having the protein immobilized thereon is filled to equilibrate the column, adding a solution containing an antibody to cause the adsorption of the antibody onto the carrier, and eluting the antibody adsorbed on the carrier using an elution solution.
Abstract: Anti-PD-L1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and uses and methods using the same.
Type:
Grant
Filed:
October 9, 2019
Date of Patent:
December 27, 2022
Assignee:
Agency for Science, Technology and Research
Abstract: The present disclosure discloses a method for expressing and preparing a bivalent bispecific antibody. In the present disclosure, each portion of a bivalent bispecific antibody and an immune hybrid protein thereof is respectively expressed in a suitable prokaryotic or eukaryotic cell system, separated and purified by high-performance affinity chromatography, and then spliced in vitro by trans-splicing reaction mediated by an intein, to prepare the bivalent specific antibody and an immune hybrid protein thereof.
Abstract: The object of the present invention is to provide a humanized or mouse-human chimeric anti-podoplanin antibody or an antibody fragment containing the antigen-binding region thereof, and the object is achieved by providing an isolated humanized or mouse-human chimeric anti-podoplanin antibody which comprises a predetermined amino acid sequence, or an antibody fragment containing the antigen-binding region thereof.
Type:
Grant
Filed:
June 14, 2019
Date of Patent:
December 20, 2022
Assignee:
JAPANESE FOUNDATION FOR CANCER RESEARCH
Inventors:
Nobuhiko Gyobu, Naoya Fujita, Mamoru Kakino, Ai Kawashima, Shinya Fujihara, Naoki Goda
Abstract: The present disclosure provides anti-BTC antibodies, methods of producing said antibodies, pharmaceutical compositions comprising said antibodies, and methods of using said antibodies. The present disclosure also provides multi-specific binding molecules, e.g., bispecific antibodies, comprising a BTC binding moiety and an anti-VEGF binding moiety.
Type:
Grant
Filed:
July 14, 2021
Date of Patent:
December 13, 2022
Assignee:
NOVARTIS AG
Inventors:
Chad Eric Bigelow, Ana Maria Carrion, James Edgar Chastain, Kirk Lee Clark, Bijan Alexandre Etemad-Gilbertson, Joy Gispati Ghosh, Shawn Michael Hanks, Nicole Haubst, Ganesh Rajan Iyer, Nina Moker, Andrew Anh Nguyen, Stephen Hedrick Poor, Yubin Qiu, Nalini Velamur Rangaswamy, Michael Stefanidakis, Engin Toksoz, Michael Zbigniew Twarog
Abstract: Provided in the present invention is a bispecific antibody which comprises an anti-MUC1 VHH antibody fragment and an anti-CD16 VHH antibody fragment. The antibody fragment used in the present invention is a variable region sequence derived from a heavy chain camelid antibody and has a high binding affinity to the antigen. Antibody fragments recognizing MUC1 and CD16 are constructed in the same antibody molecule by the invention, so that the antibody molecule can specifically bind to MUC1 and CD16 molecules to promote the killing effect of NK cells on MUC1-positive expression cells and has an inhibiting effect on the growth of MUC1-positive tumors. Also provided is a conjugate of the bispecific antibodies, a related pharmaceutical composition and use.
Abstract: The invention is concerned with a method of predicting response to a PD-1 axis inhibitor such as anti-PD-L1 antibody by determining the abundance of dendritic cells (DCs) in a tumor tissue sample. The abundance of DCs characterized by enhanced expressions of XCR1, IRF8, BATF3 and FLT3 predicts clinical response to the PD-L1 blockade 5 treatment.
Type:
Grant
Filed:
March 25, 2019
Date of Patent:
November 29, 2022
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Christian Klein, Maud Léa Mayoux, Andreas Roller, Wei Xu
Abstract: A TIGIT antibody, an antigen-binding fragment thereof, and a medical use thereof. The present invention relates to a murine antibody, a chimeric antibody, and a humanized antibody comprising a CDR region of the TIGIT antibody, and a pharmaceutical composition comprising the TIGIT antibody and the antigen-binding fragment thereof, and a use thereof as a medicament. In particular, the present invention also relates to a use of a humanized TIGIT antibody for preparing a medicament for the treatment of TIGIT-associated diseases or conditions.
Abstract: The present invention relates to human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.
Type:
Grant
Filed:
June 20, 2017
Date of Patent:
November 22, 2022
Assignee:
TeneoBio, Inc.
Inventors:
Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, Duy Pham
Abstract: The present invention provides a method for production of stable and highly specific heterodimeric immunoglobulin constructs, e.g., bispecific antibodies, retaining desirable properties of native IgG and lacking undesirable heavy chain-light chain mispairing, that can simultaneously bind two target molecules and are more potent in the treatment of complex diseases.
Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a BCMA monoclonal antibody, conferring specific immunity against BCMA positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas, multiple myeloma and leukemia.
Abstract: The invention provides a bispecific antibody construct comprising a first human binding domain capable of binding to human CDH19 on the surface of a target cell and a second domain capable of binding to human CD3 on the surface of a T cell. Moreover, the invention provides a nucleic acid encoding the antibody construct, a vector comprising the nucleic acid and a host cell transformed or transfected with the vector. Furthermore, the invention provides a process for the production of the bispecific antibody construct, a medical use of the antibody construct and a kit comprising the antibody construct. The bispecific antibody construct may be useful in the treatment of melanoma.
Type:
Grant
Filed:
July 20, 2018
Date of Patent:
November 15, 2022
Assignees:
AMGEN RESEARCH (MUNICH) GMBH, AMGEN INC.
Inventors:
Shouhua Xiao, Zheng Pan, Dineli Wickramasinghe, M. Shawn Jeffries, Chadwick Terence King, Brian Mingtung Chan, Peter Kufer, Ralf Lutterbüse, Tobias Raum, Patrick Hoffmann, Doris Rau, Roman Kischel, Bryan Lemon, Holger Wesche
Abstract: The present invention provides a bi-specific molecule which comprises: (i) a first domain which binds B cell maturation antigen (BCMA) and comprises at least part of a proliferation-inducing ligand (APRIL); and (ii) a second domain capable of activating a T cell. The invention also provides the use of such a molecule in the treatment of plasma-cell mediated diseases, such as multiple myeloma.
Type:
Grant
Filed:
October 10, 2014
Date of Patent:
November 8, 2022
Assignee:
UCL BUSINESS LTD
Inventors:
Martin Pulé, Kwee Yong, Lydia Lee, Neil Chaplin
Abstract: The present invention is directed to heterodimeric anti-LAG-3×anti-CTLA-4. Also provided are nucleic acid compositions that encode the antibodies, expression vector compositions that include the nucleic acids, and host cells that include the expression vector compositions.
Type:
Grant
Filed:
June 7, 2019
Date of Patent:
November 8, 2022
Assignee:
Xencor, Inc.
Inventors:
Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon, Alex Nisthal, Umesh S. Muchhal
Abstract: Conjugates comprising a coagulating agent conjugated to an antibody, where the antibody specifically binds an extracellular domain epitope of a mammalian PLVAP protein, and methods of using such conjugates, including methods of treating HCC by administering the conjugates or compositions thereof, such as pharmaceutical compositions.
Abstract: The present disclosure provides humanized antibodies that specifically bind to CD3 with an optimized affinity and induce T cell-mediated killing of tumour related target antigen high expressing cells with high potency but have limited killing activity on target antigen low expressing cells. The present disclosure also provides bispecific antibodies comprising a first antigen-binding domain that specifically binds to human CD3 with optimized affinity and a second antigen-binding molecule that specifically binds a tumor-related antigen. The disclosure further relates to methods of generating such humanized antibodies and bispecific antibodies for biological, diagnostic, pharmaceutical and other uses.
Type:
Grant
Filed:
August 13, 2018
Date of Patent:
October 18, 2022
Assignee:
MORPHOSYS AG
Inventors:
Thomas Tiller, Steffen Runz, Julia Neugebauer, Andreas Bültmann
Abstract: Antibody derivatives that have diminished effector function in the initial state owing to the presence of one or more disabling moieties that substantially prevent engagement of the antibody regions responsible for interaction with humoral and cellular immune system effector molecules, and methods of use thereof.
Abstract: Anti-CD33 antibodies and antigen-binding fragments thereof and anti-CD33/anti-CD3 bispecific antibodies or antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as cancer.
Type:
Grant
Filed:
May 21, 2019
Date of Patent:
October 11, 2022
Assignee:
JANSSEN BIOTECH, INC.
Inventors:
Michael Diem, Francois Gaudet, Ronan McDaid, Priyanka Nair-Gupta
Abstract: Described herein are mutations in the CH1/CL interface and CH3 constant regions of a bispecific antibody which facilitate heterodimerization and methods for the efficient production of bispecific antibodies. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
Type:
Grant
Filed:
December 28, 2016
Date of Patent:
October 4, 2022
Assignee:
Massachusetts Institute of Technology
Inventors:
Ram Sasisekharan, Kannan Tharakaraman, Vidya Subramanian, Eduardo Fleischer, Andrew Peter Hatas